BNTX

Neutral

BioNTech Impfung: Post-Pandemic Pivot Challenges Biotech Resilience

BioNTech, the company behind the COVID-19 vaccine Comirnaty, is facing a significant revenue decline as demand for its vaccine fades after the pandemi...

AD HOC NEWS 55 mins ago 0

Neutral

BioNTech SE stock (US09075V1026): Is its oncology pivot strong enough to unlock post-COVID upside?

BioNTech is shifting its focus from COVID-19 vaccines to oncology, leveraging its mRNA technology for individualized cancer therapies. While this pivo...

AD HOC NEWS 49 mins ago 0